aTyr Pharma, Inc. (LIFE) | Investment Case

1. Company Snapshot

1.a. Company Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors.

It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd.for the development and commercialization of efzofitimod for ILDs in Japan.The company was incorporated in 2005 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on LIFE

Recent developments surrounding Globe Life Inc. (GL) indicate potential headwinds. The company reported Q2 2024 earnings, with net income of $2.83 per diluted common share, compared to $2.24 in the year-ago quarter. However, multiple law firms, including Bragar Eagel & Squire, P.C., The Schall Law Firm, and Kahn Swick & Foti, LLC, have initiated investigations and class action lawsuits against Globe Life, alleging securities law violations and potential breaches of fiduciary duties by the company's board of directors. These ongoing investigations and lawsuits may pose a risk to the company's financials and reputation.

1.c. Company Highlights

Last Price	1.9
Change Percentage	2.70%
Open	1.86
Previous Close	1.85
Market Cap ( Millions)	131
Volume	267893
Year High	2.45
Year Low	1.08
M A 50	1.76
M A 200	1.59

FCF Yield	-151.12%
Dividend Yield	0.00%
ROE	-100.11%
Debt / Equity	15.40%
Net Debt / EBIDTA	-8.05%
Price To Book	1.0
Price Earnings Ratio	-1.07
Price To FCF	-0.66
Price To sales	424.9
EV / EBITDA	-1.13

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Military Metals Announces Closing of Fully Subscribed LIFE Offering

Dec -04

Source: newsfilecorp.com

Goldcliff Announces Closing of Fourth and Final Tranche of its LIFE Offering

Dec -04

Source: accessnewswire.com

NioBay Metals Announces Upsize of Brokered LIFE Offering and Concurrent Private Placement to Gross Proceeds of Up to C$7.5 Million

Dec -03

Source: globenewswire.com

Military Metals Provides Update on Financing and Files Amended LIFE Offering Document

Dec -02

Source: newsfilecorp.com

CORRECTION FROM SOURCE: Tudor Gold Announces $10 Million Brokered LIFE Offering

Dec -02

Source: newsfilecorp.com

Tudor Gold Announces $10 Million Brokered LIFE Offering

Dec -02

Source: newsfilecorp.com

Azincourt Energy Announces Private Placement Under the Listed Issuer Financing Exemption (LIFE) and Share Consolidation

Dec -02

Source: newsfilecorp.com

Metasphere Labs Announces Cancellation of Non-Brokered LIFE Offering

Dec -02

Source: thenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Innovative Medicines

Expected Growth: 15.4%

Growing demand for rare genetic disorder treatments, increasing cancer prevalence, and innovative protein-based therapeutics drive market growth, with aTyr Pharma's novel approach harnessing aminoacyl tRNA synthetases poised to capture significant market share.

7. Detailed Products

Resolaris

Resolaris is a novel, first-in-class, intravenous protein therapeutic designed to treat rare, severe, and debilitating diseases, including hereditary angioedema (HAE) and complement-mediated diseases.

ATYR1923

ATYR1923 is a novel, first-in-class, oral protein therapeutic designed to treat pulmonary sarcoidosis and other inflammatory diseases.

ATYR2810

ATYR2810 is a novel, first-in-class, oral protein therapeutic designed to treat cancer and other diseases.

8. aTyr Pharma, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

aTyr Pharma, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for the diseases they are targeting.

Bargaining Power Of Customers

aTyr Pharma, Inc. has a low bargaining power of customers due to the specialized nature of their products and the lack of alternative options for patients.

Bargaining Power Of Suppliers

aTyr Pharma, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

aTyr Pharma, Inc. has a high threat of new entrants due to the growing interest in the biotechnology industry and the potential for new companies to enter the market.

Intensity Of Rivalry

aTyr Pharma, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	14.27%
Debt Cost	3.95%
Equity Weight	85.73%
Equity Cost	10.29%
WACC	9.38%
Leverage	16.65%

11. Quality Control: aTyr Pharma, Inc. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

aTyr Pharma

A-Score: 4.6/10

Value: 7.6

Growth: 6.4

Quality: 6.8

Yield: 0.0

Momentum: 5.0

Volatility: 1.7

1-Year Total Return ->

Veracyte

A-Score: 4.3/10

Value: 1.2

Growth: 8.4

Quality: 6.4

Yield: 0.0

Momentum: 6.0

Volatility: 3.7

1-Year Total Return ->

Taysha Gene Therapies

A-Score: 4.2/10

Value: 6.2

Growth: 4.9

Quality: 4.2

Yield: 0.0

Momentum: 9.0

Volatility: 0.7

1-Year Total Return ->

Alector

A-Score: 2.8/10

Value: 7.8

Growth: 3.7

Quality: 3.7

Yield: 0.0

Momentum: 1.0

Volatility: 0.7

1-Year Total Return ->

Recursion Pharmaceuticals

A-Score: 2.8/10

Value: 6.8

Growth: 3.9

Quality: 3.4

Yield: 0.0

Momentum: 2.0

Volatility: 0.7

1-Year Total Return ->

Adverum Biotechnologies

A-Score: 2.6/10

Value: 8.0

Growth: 1.9

Quality: 3.6

Yield: 0.0

Momentum: 1.0

Volatility: 1.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

18.09%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

9.38%

aTyr Pharma, Inc. - US0021202025

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on LIFE

1.c. Company Highlights

Stable Momentum

Average Growth

Average Quality

Earnings Beats

Revenues Beats

Average Yield

Fairly Valued

Medium Volatility

Less Volatile

Cheaper

Better Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Innovative Medicines

Expected Growth: 15.4%

7. Detailed Products

Resolaris

ATYR1923

ATYR2810

8. aTyr Pharma, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: aTyr Pharma, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.9$

Current Price

1.9$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA